Adma Biologics (ADMA) Net Cash Flow (2011 - 2025)

Adma Biologics has reported Net Cash Flow for 13 years, with the latest figure at $26.2 million in Q4 2025.

• For the quarter ending Q4 2025, Net Cash Flow rose 59.64% year-over-year to $26.2 million; the trailing twelve-month figure through Dec 2025 stood at -$15.5 million (down 129.96% YoY), and the FY2025 full-year result was -$15.5 million, down 129.96% from the prior year.
• Net Cash Flow for Q4 2025 stood at $26.2 million, up from -$28.9 million in the prior quarter.
• The five-year high for Net Cash Flow was $51.6 million in Q4 2022, with the low at -$31.5 million in Q1 2025.
• Historically, Net Cash Flow has averaged $1.6 million across 5 years, with a median of -$3.8 million in 2024.
• Annual changes were most pronounced in 2024 — Net Cash Flow jumped 741.44% — and 2025, when it sank 1780.29%.
• Adma Biologics' Net Cash Flow stood at $16.7 million in 2021, then jumped by 209.48% to $51.6 million in 2022, then tumbled by 144.18% to -$22.8 million in 2023, then soared by 172.09% to $16.4 million in 2024, then soared by 59.64% to $26.2 million in 2025.
• The last three Net Cash Flow figures came in at $26.2 million (Q4 2025), -$28.9 million (Q3 2025), and $18.7 million (Q2 2025), per Business Quant data.